05:10 PM EST, 11/04/2025 (MT Newswires) -- Eupraxia Pharmaceuticals ( EPRX ) on Tuesday reported a loss of $6.4 million in the third quarter, versus a net loss of $6 million in the prior year period.

The clinical-stage biotechnology company said the increase in its loss was primarily due to higher research and development costs and general and administrative costs, partially offset by an increase in other income.

The company had no revenue in the quarter.

"The compelling 52-week data from our RESOLVE trial reported this quarter further reinforce the potential of EP-104GI as a highly effective and durable treatment for eosinophilic esophagitis," said Dr. James Helliwell, CEO of Eupraxia. "Our highest-dose cohort delivered the largest improvements in tissue health outcomes and eosinophil reduction observed to date, with no additional safety concerns."

Eupraxia said it completed an $80.5 million public offering, leaving it with $89 million of cash on hand at Sept.30, sufficient to fund operations and pipeline development into the first half of 2028.

The company's shares closed down C$0.25 to C$7.75 on the Toronto Stock Exchange.